GAITHERSBURG, Md., July 30, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced it will report its second quarter 2025 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Wednesday, August 6, 2025. Details of the event and replay are as follows:
Conference call details: | |
Date: | August 6, 2025 |
Time: | 8:30 a.m. U.S. ET |
URL to register phone: | |
Dial-in number: | (888) 880-3330 (Domestic) or |
(+1) (646) 357-8766 (International) | |
Webcast: |
Replay details: | |
Date: | Available starting at 11:30 a.m. U.S. ET, August 6, 2025, until 11:59 p.m. U.S. ET, August 13, 2025 |
Dial-in number: | (800) 770-2030 (Domestic) or |
(+1) (609) 800-9909 (International) | |
Passcode: | 3041984# |
Webcast: | ir.novavax.com/events, until September 5, 2025 |
About Novavax
Novavax, Inc. (Nasdaq: NVAX) tackles some of the world's most pressing health challenges with its scientific expertise in vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M® adjuvant. The Company's growth strategy seeks to optimize its existing partnerships and expand access to its proven technology platform via research and development innovation, organic portfolio expansion in infectious disease and beyond, and forging new partnerships and collaborations with other companies. Please visit novavax.com and LinkedIn for more information.
Contacts:
Investors
Luis Sanay, CFA
240-268-2022
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media
Giovanna Chandler
844-264-8571
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$7.49 |
Daily Change: | -0.35 -4.46 |
Daily Volume: | 4,755,695 |
Market Cap: | US$1.220B |
May 19, 2025 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load